Rani Therapeutics Announces Successful Drug Delivery Of High-Capacity Pill In Preclinical Studies
Portfolio Pulse from Happy Mohamed
Rani Therapeutics (NASDAQ:RANI) announced successful preclinical studies of its high-capacity oral biologics device, RaniPill® HC. The device achieved a 90% success rate in delivering teriparatide in two studies. The RaniPill® HC can deliver a 500% higher drug payload than Rani's existing oral biologics capsule, potentially enabling the delivery of 90+ additional drug candidates. Rani plans to continue preclinical testing and initiate a Phase 1 study of adalimumab RT-105.
September 07, 2023 | 8:24 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Rani Therapeutics' successful preclinical studies of RaniPill® HC could potentially open up a significant market opportunity. The company's stock may see positive movement in the short term.
The successful preclinical studies of RaniPill® HC, which can potentially deliver 90+ additional drug candidates, represent a significant advancement for Rani Therapeutics. This could potentially open up a significant market opportunity for the company, which could positively impact its stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100